Intra-Cellular Therapies Inc (NASDAQ:ITCI)
| 52.62 Delayed Data As of 3:59pm ET |  -1.82 / -3.34%Today’s Change | 42.01 Today|||52-Week Range 67.05 | -0.57% Year-to-Date |
Latest ITCI News | Press Releases
| Insider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies Inc Sep 20 / GuruFocus News - Paid Partner Content |
Today’s Trading
| Previous close | 54.44 |
| Today’s open | 53.96 |
| Day’s range | 52.62 - 54.07 |
| Volume | 27,015 |
| Average volume (3 months) | 646,610 |
| Market cap | $5.3B |
Data as of 3:59pm ET, 09/21/2023
Growth & Valuation
| Earnings growth (last year) | +22.08% |
| Earnings growth (this year) | +15.94% |
| Earnings growth (next 5 years) | +98.10% |
| Revenue growth (last year) | +198.69% |
| P/E ratio | NM |
| Price/Sales | 19.88 |
| Price/Book | 7.95 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| DCHPFDechra Pharmaceutica... | 0.00 | 0.00% |
| ---- | ||
| ALKSAlkermes Plc | -0.44 | -1.46% |
| ---- |
Data as of 4:00pm ET, 09/21/2023
Financials
| Next reporting date | November 7, 2023 |
| EPS forecast (this quarter) | -$0.61 |
| Annual revenue (last year) | $250.3M |
| Annual profit (last year) | -$256.3M |
| Net profit margin | -102.37% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New York, New York |
Forecasts
